Because of recent technological advances, together with unrealized expectations from current lead generation strategies, there is a renewed interest in natural products in the field of drug discovery. - Jinan University Researcher
Rochester, NY (PRWEB) October 04, 2013
Drugs like acyclovir (ACV) are the standard treatment against the herpes virus (HSV) (1). However, more and more strains of the herpes virus have learned to protect themselves against these drugs. Scientists call this situation “drug resistance.” Drug resistance has become a serious problem in the last few years (1).
Normally, drug resistant strains show up in people with a weak immune system. However, researchers found that drug resistant strains were also widespread in individuals with a healthy immune system (1). Thus, there is a need for safe and effective, new antiviral products.
Study authors wrote that “resistant HSV occurs frequently in clinical therapy when using nucleoside analogs, including ACV and penciclovir (PCV) together with their respective prodrugs valacyclovir and famciclovir. Duan et al. revealed that ACV-resistant HSV-1 isolates in immunocompetent patients with herpes keratitis had a relatively high prevalence (1).”
Because the standard drug discovery process failed, there is a growing need to look beyond the traditional chemical route. According to the Jinan University researchers, “Because of recent technological advances, together with unrealized expectations from current lead generation strategies, there is a renewed interest in natural products in the field of drug discovery (1).”
Thousands of studies showed that many natural ingredients work effectively against the herpes virus. As the study authors noted, “Natural products, particularly traditional medicines, which have provided multiple novel drug leads, are known to be an important source of anti-HSV agents (1).”
The CBCD believes that natural products can be developed, which are safe and effective against the herpes virus. Because of that belief, the Center became excited when polyDNA asked the CBCD to test its flagship, natural antiviral product. The Center was happy to discover that a post-marketing clinical study provided evidence for the safety and effectiveness of Gene-Eden-VIR. The study was published in the peer reviewed, scientific journal Pharmacology & Pharmacy, in a special edition on Advances in Antiviral Drugs (2).
The CBCD study showed that Gene-Eden-VIR reduced symptoms that come from a herpes infection. Study authors wrote that, “individuals infected with herpes…reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR (2).” The study authors also wrote that “We observed a statistically significant decrease in the severity, duration, and frequency of symptoms (2).”
To view the entire paper on Gene-Eden-VIR,
We invite the media to contact us for interviews at: info(at)buy-gene-eden(dot)com or phone 585-250-9999.
The Center for the Biology of Chronic Disease (CBCD, http://www.cbcd.net) is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments.
The CBCD published the “Purple” book by Dr. Hanan Polansky. The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between foreign DNA and the onset of chronic diseases. Dr. Polansky’s book is available as a free download from the CBCD website.